Initial data on basiliximab in critically ill children undergoing heart transplantation

Journal of Heart and Lung Transplantation

Volumn 24, Issue 9, 2005, Pages 1284-1288

  Ford, Katrina A ^a,c   Cale, Catherine M ^b   Rees, Philip G ^c   Elliott, Martin J ^c   Burch, Michael ^c  

^a Pharmacy Department   (United Kingdom)

^b Immunology Department   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; TACROLIMUS;

ADOLESCENT; ARTICLE; BIOPSY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION; HEART TRANSPLANTATION; HUMAN; INFANT; INFECTION; KIDNEY DISEASE; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZATION; RECIPIENT; REDUCTION;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CALCINEURIN; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY; KIDNEY DISEASES; MALE; PHOSPHOPROTEINS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; TACROLIMUS;

EID: 24344486455     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2004.08.017     Document Type: Article

References (25)

1. S. Itescu, T.C.M. Tung, E.M. Burke An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients Lancet 352 1998 263 270
2. B.A. Pietra, M.M. Boucek Coronary artery vasculopathy in pediatric cardiac transplant patients the therapeutic potential of immunomodulators Pediatr Drugs 5 2003 513 524
3. S. Chaparro, S. Gao, M. Perlroth Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients thirty years' experience at our hospital J Heart Lung Transplant 20 2001 161 162
4. L.D. Sharples, C.H. Jackson, J. Parameshwar Diagnostic accuracy of coronary angiography and risk factors for post-heart transplant cardiac allograft vasculopathy Transplantation 76 2003 679 682
5. C. Chin, D.C. Naftel, T.P. Singh Risk factors for recurrent rejection in pediatric heart transplantation a multicentre experience J Heart Lung Transplant 23 2004 178 185
6. M. Rizeq, M.A. Masek, M.E. Billingham Acute rejection significance of elapsed time after transplantation J Heart Lung Transplant 13 1994 862 868
7. S.A. Webber, D.C. Naftel, J. Parker Late rejection episodes more than 1 year after pediatric heart transplantation risk factors and outcomes J Heart Lung Transplant 22 2003 869 875
8. R.F. English, S.A. Pophal, S.U. Bacuanu Long-term comparison of tacrolimus and cyclosporine induced nephrotoxicity in pediatric heart-transplant recipients Am J Transplantation 2 2002 769 773
9. A. Asante-Korang, G.J. Boyle, S.A. Webber Experience of FK506 immune suppression in pediatric heart transplantation a study of long-term adverse effects J Heart Lung Transplant 15 1996 415 422
10. C. Esposito, L. Semeraro, N. Bellotti Risk factors for chronic renal dysfunction in cardiac allograft recipients Nephron 84 2000 21 28
11. F.L. Adajar, C.E. Lawless, K. Malinsowska Outcome of heart transplant in patients with renal insufficiency J Heart Lung Transplant 20 2001 248
12. I. Saeed, C.A. Rogers, A.J. Murday Immediate renal replacement therapy and outcome after cardiac transplantation - multivariate analysis of risk factors J Heart Lung Transplant 20 2001 257
13. A.O. Ojo, P.J. Held, F.K. Port Chronic renal failure after transplantation of a non-renal organ N Engl J Med 349 2003 931 940
14. W.S. Cherikh, H.M. Kauffman, M.A. McBride Association of the type of induction immunosuppression with post-transplant lymphoproliferative disorder, graft survival and patient survival after primary kidney transplantation Transplantation 76 2003 1289 1293
15. P.S. MacDonald, J. Mundy, A.M. Keogh A prospective randomised study of prophylactic OKT-3 versus equine anti-thymocyte globulin after heart transplantation - increased morbidity with OKT-3 Transplantation 55 1993 110 116
16. B.P. Griffith, R.L. Kormos, J.M. Armitage Comparative trial of immunoprophylaxis with RATG versus OKT-3 J Heart Transplant 9 3 Pt 2 1990 301 305
17. R.L. Kormos, D.B. Herlan, J.M. Armitage Monoclonal versus polyclonal antibody therapy for prophylaxis against rejection after heart transplantation J Heart Transplant 9 1990 1 10
18. A. Laske, A. Gallino, J. Schneider Prophylactic cytolytic therapy in heart transplantation monoclonal versus polyclonal antibody therapy J Heart Lung Transplant 11 1992 557 563
19. Novartis Pharmaceuticals UK Limited. Simulect (basiliximab): summary of product characteristics. Accessed May 23, 2003. Available at: http://emc.medicines.org.uk.
20. C.C. Baan, I.C. van Reimskijk-Overbeeke, M.J.A.M. Boelaars-van Haperen Inhibition of the IL-15 pathway in anti-CD25 mAB treated renal allograft recipients Transpl Immunol 10 2002 81 87
21. G. Sterkers, V. Baudouin, H. Ansart-Perenne Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts Transplant Proc 32 2000 2757 2759
22. M.C. Morris, C.W. Allanby, P. Toseland Evaluation of a height/plasma creatinine formula in the measurement of glomerular filtration rate Arch Dis Child 57 1982 611 615
23. G. Zacchello, M. Bondio, O.S. Saia Simple estimate of creatinine clearance from plasma creatinine in neonates Arch Dis Child 57 1982 297 300
24. D. Adu, P. Cockwell, N.J. Ives Interleukin-2 receptor monoclonal antibodies in renal transplantation meta-analysis of randomised trials BMJ 326 2003 789 (12 April)
25. A.P. Goldman, M. de Leval, K. Brown The waiting game bridging to paediatric heart transplantation Lancet 362 2003 1967 1970